Monday, November 21, 2022 2:54:16 PM
before the American Exchange most likely boots them back because of not have the minimum Bid price. They can file for an extension of 6 months and I would think that is what they will do.
From the Press Release Date Nov 17:
Ampio’s continued listing on the Exchange will be predicated on it demonstrating compliance with Section 1003(f)(v) of the NYSE American Company Guide through a period of at least December 23, 2022. The Company will update shareholders if and when it receives notification from the NYSE American that it has achieved compliance on this matter.
Recent AMPE News
- Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation • PR Newswire (US) • 04/03/2024 06:33:00 PM
- Ampio Announces Voluntary Delisting and SEC Deregistration • PR Newswire (US) • 03/25/2024 09:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/05/2024 05:15:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 08:49:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/28/2024 08:48:05 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/28/2024 08:47:17 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/28/2024 08:46:20 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 02/28/2024 08:45:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 02:31:23 PM
- Ampio Provides Update on Results from Pre-IND Enabling Studies • PR Newswire (US) • 02/14/2024 10:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:31:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/25/2024 09:18:53 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/24/2024 10:16:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:20:20 PM
- Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions • PR Newswire (US) • 01/11/2024 09:15:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/21/2023 09:25:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:10:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 01:30:24 PM
- Ampio Pharmaceuticals to Present at the Emerging Growth Conference • PR Newswire (US) • 10/31/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 06:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 06:56:04 PM
- Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201 • PR Newswire (US) • 10/05/2023 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 08:15:24 PM
- Ampio Pharmaceuticals to Present at the Emerging Growth Conference • PR Newswire (US) • 09/26/2023 01:15:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM